All In Biotech

Drug Trial Radar · NCT03165409

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma

Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,828

Actual

Start

Feb 27, 2017

Primary completion

Sep 30, 2017

Study completion Sep 30, 2017

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 24, 2017

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.

Conditions

  • Melanoma

Interventions

  • NivolumabBiological

    Melanoma intervention

  • IpilimumabBiological

    Melanoma intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with less frequent general outpatient visitsTime frame: Approximately 5 years
  2. Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with more frequent general outpatient visitsTime frame: Approximately 5 years
  3. Treatment-related and all-cause AE costs for nivolumab/ipilimumab combination therapy for metastatic melanomaTime frame: Approximately 5 years
  4. Treatment-related and all-cause AE costs for nivolumab monotherapy for metastatic melanomaTime frame: Approximately 5 years
  5. Treatment-related and all-cause AE costs for ipilimumab monotherapy for metastatic melanomaTime frame: Approximately 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bristol-Myers Squibb

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.